US Stock MarketDetailed Quotes

ROIV Roivant Sciences

Watchlist
  • 10.855
  • -0.045-0.41%
Trading Apr 25 15:21 ET
8.75BMarket Cap2.00P/E (TTM)

About Roivant Sciences Company

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Company Profile

SymbolROIV
Company NameRoivant Sciences
Listing DateDec 14, 2020
Founded2014
CEOMr. Matthew Gline
MarketNASDAQ
Employees904
Securities TypeOrdinary Shares
Fiscal Year Ends03-31
Address50 Broadway,7th Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeSW1H 0BD
Phone44-207-400-3347
Websitehttp://www.roivant.com

Company Executives

  • Name
  • Position
  • Salary
  • Matthew Gline
  • Chief Executive Officer and Director
  • 48.98M
  • Richard Pulik
  • Chief Financial Officer
  • --
  • Rakhi Kumar
  • Chief Accounting Officer
  • --
  • Dr. Eric Venker, M.D.,Pharm.D.
  • Co-President and Chief Operating Officer
  • 48.49M
  • Dr. Mayukh Sukhatme
  • Co-President and Chief Investment Officer
  • 48.93M
  • Ilan Oren
  • Chairman of the Board
  • 403.53K
  • Keith Manchester
  • Independent Director
  • 391.03K
  • Daniel Gold
  • Independent Director
  • 401.03K
  • Meghan M. Fitzgerald, Ph.
  • Independent Director
  • 2.34K
  • James C. Momtazee
  • Independent Director
  • 394.31K
  • Melissa B. Epperly
  • Independent Director
  • 654.02K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg